AUTHORS
Mo Cheng Jr, MD,PHD, Wenke Li, MD2, Mengyuan Liu, MD3, Kexing Ren Jr, MD,PHD4, Xi Chen, MD5, Chunli Yang Jr, MD,PHD6, Beibei Yang Jr, MD,PHD7, Liqun Zou, MD8
AFFILIATIONS
1 West China Hospital of Sichuan University, Chengdu, Sichuan, China
2 West China Hospital of Sichuan University, Chengdu, Sichuan, China
3 West China Hospital of Sichuan University, Chengdu, Sichuan, China
4 West China Hospital of Sichuan University, Chengdu, Sichuan, China
5 West China Hospital of Sichuan University, Chengdu, Sichuan, China
6 West China Hospital of Sichuan University, Chengdu, Sichuan, China
7 West China Hospital of Sichuan University, Chengdu, Sichuan, China
8 West China Hospital of Sichuan University, Chengdu, Sichuan, China
ABSTRACT
Introduction: Primary central nervous system lymphoma (PCNSL) is an aggressive non-Hodgkin lymphoma, and there is no consensus on the optimal treatment strategy. High-dose methotrexate (HD-MTX) remains the cornerstone of induction therapy for PCNSL, and drug penetration across the blood-brain barrier (BBB) remains a major therapeutic challenge. Bruton tyrosine kinase inhibitors (BTKis) suppress proliferation and survival by targeting B-cell receptor/NF-κB signaling, while their small-molecule properties enhance BBB penetration and help address this therapeutic barrier. BTKis are increasingly incorporated into first-line combination therapy for PCNSL. However, current evidence is derived mainly from small single-arm studies without control groups. In this meta-analysis, we evaluated the efficacy and safety of BTKis in patients with newly diagnosed PCNSL.
Methods: This systematic review and meta-analysis was conducted in accordance with the PRISMA guidelines. PubMed, Web of Science, Embase, and conference proceedings were searched from inception through July 15, 2026. Of 815 articles identified, 618 unique records were screened, and 70 full-text articles were assessed for eligibility. We included studies reporting the efficacy or safety of BTKi-based combination regimens in newly diagnosed PCNSL. When multiple reports described the same trial at different stages, the report with the longest follow-up or most complete data was selected. Outcomes included objective response rate (ORR), complete response (CR), 24-month progression-free survival (PFS), and 24-month overall survival (OS). Prespecified exploratory subgroup analyses were conducted according to the BTKi agent and whether the regimen included methotrexate (MTX) or rituximab. Heterogeneity was assessed using the I² statistic and Cochran’s Q test, and subgroup differences were evaluated using interaction tests. PROSPERO: CRD420261458003.
Results: A total of 32 studies comprising 841 patients were included. The pooled CR/CRu rate was 71.3% (95% CI, 63.6%–78.2%; I² = 75.8%; P < .00001). Because one study did not report ORR, the ORR analysis included 826 patients; the pooled ORR was 89.4% (95% CI, 86.6%–92.1%; I² = 14.6%; P = .419). For the PFS and OS analyses, follow-up ranged from 11.6 to 33.3 months. The pooled 24-month PFS rate was 63.5% (95% CI, 56.4%–69.8%; I² = 50.9%; P = .018; 16 studies, 476 patients), and the pooled 24-month OS rate was 82.0% (95% CI, 70.8%–89.2%; I² = 81.0%; P < .00001; 12 studies, 384 patients).
In subgroup analyses by BTKi agent, the CR/CRu rates were 76.0% with zanubrutinib (95% CI, 61.0%–87.4%), 72.7% with ibrutinib (95% CI, 51.3%–88.8%), and 67.9% with orelabrutinib (95% CI, 55.3%–78.9%), with an interaction P value of .632. The ORR was highest with ibrutinib at 90.3% (95% CI, 78.9%–97.9%), followed by orelabrutinib at 89.7% (95% CI, 85.3%–93.9%) and zanubrutinib at 88.0% (95% CI, 83.3%–91.8%), with an interaction P value of .909. When stratified by MTX use, the CR/CRu and ORR rates were 72.9% (95% CI, 64.7%–80.2%) and 90.4% (95% CI, 86.8%–93.7%), respectively, for MTX-containing regimens, compared with 48.1% (95% CI, 19.6%–78.5%) and 83.8% (95% CI, 74.1%–91.4%) for regimens without MTX. When stratified by rituximab use, the CR/CRu and ORR rates were 74.2% (95% CI, 65.6%–81.6%) and 90.2% (95% CI, 87.4%–93.0%), respectively, for rituximab-containing regimens, compared with 56.5% (95% CI, 39.3%–72.9%) and 82.0% (95% CI, 74.8%–89.3%) for regimens without rituximab.
12 studies comprising 288 patients provided complete safety data. The pooled incidence of any-grade adverse events was 99.3% (95% CI, 95.9%–100.0%; I² = 50.7%; P = .022). The most common events were anemia (71.5%), leukopenia (61.3%), and neutropenia (51.3%). The pooled incidence of grade 3 or higher adverse events was 42.1% (95% CI, 21.7%–67.4%; I² = 82.6%; P < .00001). The most common grade 3 or higher events were leukopenia (22.9%), neutropenia (18.9%), infection (15.6%), and thrombocytopenia (12.9%).
Conclusion: BTKi-containing regimens showed high response rates and favorable 24-month survival outcomes in newly diagnosed PCNSL. No significant differences in efficacy were observed among the individual BTKis, and combinations incorporating MTX or rituximab may represent key components associated with favorable outcomes. Adverse events were predominantly hematologic and were generally manageable. Further validation in prospective randomized controlled trials is warranted.
DISCLOSURES
Mo Cheng Jr, MD,PHD: No relevant conflicts of interest to declare.